Publications by authors named "C Priesner"
Article Synopsis
- The introduction highlights the rapid growth of point-of-care (POC) manufacturing for chimeric antigen receptor (CAR) modified T cells, particularly focusing on anti-CD20 CAR T cells for melanoma patients in a phase I clinical trial.
- The methods used involved producing CD20 CAR T cells using a second-generation lentiviral vector on the CliniMACS Prodigy® platform, demonstrating high purity and functionality across two production sites.
- Results confirmed a sufficient expansion and activation capability of the CAR T cells, revealing interindividual differences in their response, thereby supporting the effectiveness of the CliniMACS Prodigy® for decentralized CAR T cell manufacturing.
Advanced Therapy Medicinal Products and the Changing Role of Academia.
Transfus Med Hemother
June 2022
Academic institutions coin the ATMP landscape but do not possess an industry-like capacity to vigorously pursue the full developmental pathway to marketing authorization. At the same time, industry has fostered clinical trials with ATMPs, brought the first products to marketing authorization, and defined novel modes of interaction with academia. A regulatory niche for local manufacturing of ATMPs within an academic institution had been foreseen in Regulation (EU) 1394/2007 under the term "Hospital Exemption" but remained ill-defined.
View Article and Find Full Text PDFAdenovirus (HAdV) infections confer a high risk of morbidity and mortality for immunocompromised patients after stem cell transplantation (SCT). Treatment with standard antiviral drugs is of limited efficacy and associated with a high rate of adverse effects. HAdV-specific T cells are crucial for sustained viral elimination and the efficacy of adoptive T-cell therapy with donor-derived HAdV-specific T cells has been reported by several investigators.
View Article and Find Full Text PDFClinical studies using autologous CAR T cells have achieved spectacular remissions in refractory CD19+ B cell leukaemia, however some of the patient treatments with CAR T cells failed. Beside the heterogeneity of leukaemia, the distribution and senescence of the autologous cells from heavily pretreated patients might be further reasons for this. We performed six consecutive large-scale manufacturing processes for CD20 CAR T cells from healthy donor leukapheresis using the automated CliniMACS Prodigy® platform.
View Article and Find Full Text PDFBackground And Aims: The infusion of enriched CMV-specific donor T-cells appears to be a suitable alternative for the treatment of drug-resistant CMV reactivation or infection after both solid organ and hematopoietic stem cell transplantation. Antiviral lymphocytes can be selected from apheresis products using the CliniMACS Cytokine-Capture-System either with the well-established CliniMACS Plus (Plus) device or with its more versatile successor CliniMACS Prodigy (Prodigy).
Methods: Manufacturing of CMV-specific T-cells was carried out with the Prodigy and Plus in parallel starting with 0.